Keywords: biogen, starts, phase, iii, trials, amevive, plaque

Biogen starts Phase III trials of Amevive in plaque psoriasis - update

Article | 08 December 1999

Print This

Shares in Biogen rose nearly 9% to $77 on anticipation of positiveresults from its Phase II trial of Amevive (recombinant LFA-3IgG1 ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in